Browsing Tag
Mersana Therapeutics
4 posts
Day One Biopharmaceuticals moves to acquire Mersana Therapeutics in $285m cancer-drug deal
Find out how Day One Biopharmaceuticals’ $285 million acquisition of Mersana Therapeutics could reshape the rare-cancer ADC landscape today.
Mersana Therapeutics reports positive phase 1 data for novel ADC in triple-negative breast cancer
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical innovator, has announced promising early clinical data from its Phase 1 trial…
Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its…
Merck and Mersana Therapeutics to co-develop new immunostimulatory ADCs
Merck has announced a collaboration with US-based Mersana Therapeutics to discover new antibody-drug conjugates (ADCs) by leveraging the…